» Articles » PMID: 15842404

Sulfasalazine and Dermatitis Herpetiformis

Overview
Specialty Dermatology
Date 2005 Apr 22
PMID 15842404
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Dermatitis herpetiformis that is unable to be controlled using dapsone and a gluten-free diet presents a therapeutic challenge. Three cases that responded well to sulfasalazine are presented. Two cases, who were unable to tolerate dapsone, had a rapid response to sulfasalazine, without apparent side-effects. The third case with dapsone-responsive blistering dermatoses, presumed to be dermatitis herpetiformis on the basis of serology, showed an excellent clinical response to sulfasalazine, but after 6 weeks of therapy had to cease it because of side-effects. Sulfasalazine is metabolized variably to sulfapyridine, a sulphonamide known to be an effective therapy for dermatitis herpetiformis but no longer available. Sulfasalazine should be considered as a management option for dermatitis herpetiformis.

Citing Articles

Current and Innovated Managements for Autoimmune Bullous Skin Disorders: An Overview.

Chu K, Yu H, Yu S J Clin Med. 2022; 11(12).

PMID: 35743598 PMC: 9224787. DOI: 10.3390/jcm11123528.


Dermatitis Herpetiformis: An Update on Diagnosis, Disease Monitoring, and Management.

Nguyen C, Kim S Medicina (Kaunas). 2021; 57(8).

PMID: 34441049 PMC: 8400185. DOI: 10.3390/medicina57080843.


Sulfasalazine in dermatology: A lesser explored drug with broad therapeutic potential.

Mushtaq S, Sarkar R Int J Womens Dermatol. 2020; 6(3):191-198.

PMID: 32637543 PMC: 7330441. DOI: 10.1016/j.ijwd.2020.01.009.


Consensus on the treatment of autoimmune bullous dermatoses: dermatitis herpetiformis and linear IgA bullous dermatosis - Brazilian Society of Dermatology.

Vale E, Dimatos O, Porro A, Santi C An Bras Dermatol. 2019; 94(2 Suppl 1):48-55.

PMID: 31166403 PMC: 6544034. DOI: 10.1590/abd1806-4841.2019940208.


[34-year-old male with groups of blisters and erythematous papules on the extremities : Preparation for the specialist examination: part 39].

Gobel M Hautarzt. 2019; 70(Suppl 1):50-52.

PMID: 30976875 DOI: 10.1007/s00105-018-4332-1.